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Review 
Introduction
Breast cancer (BC) is recognized as a complex and het-
erogeneous disease due to the diversity of its molecular 
features, range of multiple morphologic subtypes, and the 
differences seen in response to therapy and patient out-
comes (1). Current treatment for metastatic BC (MBC) in-
cludes hormonal therapy or chemotherapy. Taxanes and 
anthracyclines are the most active chemotherapy agents in 
BC (1). Furthermore, approaches combining  antiangiogenic 
agents, such as bevacizumab, with standard chemother-
apy have been shown in clinical trials to prolong prog­
ression­free survival (PFS) without causing unacceptable 
toxicity.
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ABStRACt
Purpose: Bevacizumab, a humanized, anti­vascular endothelial growth factor­A monoclonal antibody, has shown 
efficacy in a number of cancers. However, its use in metastatic breast cancer (MBC) remains controversial. 
Methods: A literature review using the PubMed database was performed to update the currently available clini-
cal trials evidence on bevacizumab in the first­line treatment of breast cancer. In addition, the proceedings of 
selected oncology annual meetings were searched for relevant presentations.
Results: This article reviews the available evidence for bevacizumab as first­line therapy for MBC and discusses its cur-
rent and future applicability in the management of MBC. Three phase III trials (ECOG­2100, AVADO, RIBBON­1) dem-
onstrated that the addition of bevacizumab to chemotherapy is well­tolerated and improves progression­free survival 
and objective response rates in the first­line setting. These findings were supported by a large clinical practice­based 
study (ATHENA) and a recent clinical trial in which bevacizumab added to paclitaxel showed notable activity in triple­
negative MBC. However, bevacizumab has thus far not demonstrated a significant benefit in overall survival.
Conclusions: The addition of bevacizumab to chemotherapy is well­tolerated and produces substantial improve-
ments in overall response rate and progression­free survival, compared with chemotherapy alone, in advanced 
HER2­negative breast cancer. Nevertheless, it has thus far not demonstrated a significant benefit in overall sur-
vival. Whether prolongation of progression­free survival is enough to consider bevacizumab efficacious is un-
clear. Based on the available clinical trials results, bevacizumab is a part of the complex therapeutic strategy of 
advanced HER2­negative breast cancer.
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There is a firm basis to support the rationale of employ-
ing antiangiogenic agents in the treatment of cancer. It is 
well­documented that organ growth and repair is depen-
dent on angiogenesis, the physiologic process leading to the 
formation of new blood vessels. Disturbance of the tightly 
regulated physiologic balance underlying angiogenesis is an 
important factor in the development of a number of patho-
logic processes, such as inflammatory conditions, malignan-
cies, and vascular and immune disorders (2). Tumor growth 
and the development of metastatic disease is dependent on 
angiogenesis. Vascular endothelial growth factor (VEGF) is 
thought to play a critical role in tumor angiogenesis (3) by 
stimulating the proliferation and migration of vascular en-
dothelial cells, inhibiting apoptosis and antigen­presenting 
dendritic cells, inducing extracellular matrix remodeling, and 
increasing vascular permeability and vasodilation (4). Among 
various isoforms of VEGF, VEGF­A has been demonstrated to 
be the most potent in determining vasodilation and tumor 
angiogenesis, and its function is mediated by binding to VEGF 
receptors 1 and 2 (VEGFR­1 and VEGFR­2) (5).
A hypothesis generated by Folkman (6) in 1971 proposed 
that tumor progression could be prevented by interference 
with tumor angiogenesis, causing inhibition of new blood 
vessel formation and stimulating the loss of existing vessels. 
Furthermore, as proposed by Jain (7), tumor vessels appear to 
be structurally and functionally abnormal and are tightly associ-
ated with stabilizing pericytes and less dependent than normal 
vessels on VEGF for survival. So, unlike the counterpart of em-
bryogenically derived blood vessels, the vasculature of tumors 
is chaotic and poorly organized, with evidence of hyperperme-
able, irregularly shaped, tortuous, dilated, and saccular blood 
vessels characterized by restricted blood flow (7). Vascular en-
dothelial growth factor inhibition causes these immature blood 
vessels to be “normalized.” Thus, following anti­VEGF therapy, 
a higher percentage of pericyte­associated blood vessels in the 
tumor vasculature are able to function more efficiently, at least 
transiently. The associated improvement in blood flow within 
the tumor enhances the delivery of cytotoxic chemotherapy 
(8). Besides, antiangiogenic therapy results in the reduction of 
interstitial pressure and thereby facilitates tissue penetration 
of chemotherapy (9). Consequently, VEGF blockade with beva-
cizumab or another antiangiogenic agent may enhance the an-
titumor effect of chemotherapy (5, 6). Furthermore, levels of 
VEGF also affect response to endocrine therapy, regardless of 
steroid hormone receptor status. 
In advanced BC, the presence of a high tumor VEGF 
level was found to be an independent marker predicting 
a poor response to first­line endocrine therapy (10) or to 
both first­line endocrine therapy (tamoxifen) and first­line 
chemotherapy (11).
Bevacizumab (Genentech Inc., South San Francisco, CA, 
USA) is a humanized monoclonal antibody against all VEGF­A 
isoforms, and it prevents the binding of VEGF to receptors on 
vascular endothelial cells, leading to the inhibition of angio-
genesis and tumor growth. It has been shown to be effective 
in colorectal cancer, non-small-cell lung cancer, renal cell car-
cinoma, ovarian carcinoma, cervical cancer, and glioblastoma 
multiforme (12­17). However, to date, in BC, bevacizumab 
has generated more controversies than any other targeted 
therapy. 
In February 2008, the US Food and Drug Administration 
(FDA), based on promising results of the Eastern Cooperative 
Oncology Group (ECOG) 2100 trial (18), granted accelerated 
approval to bevacizumab in combination with paclitaxel for 
the first­line treatment of HER2­negative MBC. However, on 
July 20, 2010, the Oncologic Drugs Advisory Committee of the 
FDA’s Center for Drug Evaluation and Research voted against 
the combination of bevacizumab with chemotherapy for the 
first­line treatment of MBC (19). A definitive announcement 
by the FDA that revoked approval of bevacizumab for this in-
dication followed (20).
Bevacizumab is still approved in several countries as 
first­line treatment of advanced BC. European regulatory 
authorities came to a different conclusion than the FDA, 
and bevacizumab not only continues to be an accepted 
option for MBC in Europe but has been approved by the 
European Medicines Agency’s Committee for Medicinal 
Products for Human Use in an extended indication: MBC in 
combination with capecitabine as first­line therapy when a 
taxane/anthracycline combination cannot be used.
The difference in the regulatory status of bevacizumab in 
the United States and Europe has been the subject of debate, 
and the regulatory authorities reached different conclusions 
regarding its clinical benefit. This article reviews the available 
data on the use of bevacizumab in the first­line treatment of 
MBC and examines these findings in the context of the FDA’s 
revocation of its approval in the United States. 
Methods
A literature search using the PubMed database identified 
English­language reports of clinical trials of bevacizumab in 
the first­line treatment of BC. In addition, the proceedings of 
the San Antonio Breast Cancer Symposium, European Society 
of Medical Oncology, and American Society of Clinical Oncol-
ogy annual meetings were searched for presented abstracts 
using the following terms: bevacizumab and breast cancer or 
chemotherapy or efficacy or safety or cost. Each study was 
reviewed and phase III trials in patients with locally recur-
rent BC or MBC who had never been treated for metastatic 
disease and who received bevacizumab in combination with 
standard chemotherapy or broad community­based popula-
tion were evaluated (Fig. 1).
Results
Three phase III trials tested the addition of bevacizumab 
to chemotherapy in the first­line setting (Tab. I).
ECOG 2100
The ECOG 2100 trial compared the efficacy and safety of 
weekly paclitaxel plus bevacizumab with paclitaxel alone in 
722 patients with MBC (18). The primary endpoint of the study 
was PFS. Patients were randomly assigned to receive weekly 
paclitaxel (90 mg/m2) on days 1, 8, and 15 every 28 days ei-
ther alone or in combination with bevacizumab (10 mg/kg) 
on days 1 and 15. Patients continued therapy in the absence 
of disease progression or prohibitive toxicity. Median PFS was 
11.8 months for the combination of paclitaxel/ bevacizumab 
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tABLE I - Phase III studies of bevacizumab plus chemotherapy as first­line therapy for advanced breast cancer
Study Arms Patients PFS, mo Overall  
response rate, % 
patients
OS, mo Crossover
E2100 (Miller 
et al 2007) (18)
Bv 10 mg/kg q2w plus paclitaxel 90 mg/m2 
on days 1, 8, and 15 q4w (n = 368) or pacli-
taxel alone (n = 354)
722 11.3 vs 5.8 HR = 0.48 
p<0.0001
48.9 vs 22.2 
p<0.0001
26.7 vs 25.2 
HR = 0.88 
p = 0.16
Not allowed
AVADO (Miles 
et al 2010) (22)
Bv 7.5 mg/kg + docetaxel 100 mg/m2 on day 
1q3w (n = 248) vs placebo + docetaxel at 
same dose (n = 241) 
736 9.0 vs 8.1 stratified 
HR = 0.8 
p = 0.045
55.2 vs 46.4 
p = 0.0739
30.8 vs 31.9 
HR = 1.05 
p = 0.72
Allowed
Bv 15 mg/kg + docetaxel 100 mg/m2 on day 1 
q3w (n = 247) vs placebo + docetaxel at same 
dose (n = 241)
10.0 vs 8.1 stratified 
HR = 0.67 
p = 0.0002
64.1 vs 46.4 
p = 0.0003
30.2 vs 31.9 
HR = 1.03 
p = 0.85
RIBBON-1 
(Robert et al 
2011) (23)
Bv 15 mg/kg q3w + cape 2,000 mg/m2 for  
14 days (n = 409) vs placebo + cape  
2,000 mg/m2 for 14 days (n = 206)
1,237 8.6 vs 5.7 HR = 0.688 
p = 0.0002
35.4 vs 23.6 
p = 0.0097
29.0 vs 21.2 
p = 0.2707
Allowed
Bv 15 mg/kg q3w + taxane/anthracycline 
q3w (n = 415) vs placebo+ taxane/anthracy-
cline q3w (n = 207)
9.2 vs 8.0 HR = 0.644 
p<0.0001
51.3 vs 37.9 
p = 0.0054
25.2 vs 23.8 
p = 0.8298
Bv = bevacizumab; cape = capecitabine; HR = hazard ratio; OS = overall survival; PFS = progression-free survival; q2w = every 2 weeks; q3w = every 3 weeks;  
q4w = every 4 weeks.
Fig. 1 - Selection process for clini-
cal trials of bevacizumab in first­line 
HER2­negative metastatic breast 
cancer included in the analysis.
were also validated by an independent review (21). The 
combination of bevacizumab with weekly paclitaxel proved 
a tolerable regimen, with similar low rates of hematologic, 
gastrointestinal, and musculoskeletal adverse events in each 
group. Rates of grade 3 or 4 neuropathy (23.6% vs 17.6%; 
p = 0.03), infection (9.3% vs 2.9%; p<0.001), and fatigue (8.5% 
vs 4.9%; p = 0.04) were higher in the combination group. 
versus 5.9 months for paclitaxel alone (hazard ratio [HR] 0.6; 
p<0.001). Overall, adding bevacizumab to paclitaxel signifi-
cantly improved the objective response rate (ORR) (36.9% 
vs 21.2%; p<0.001). Combined therapy increased the 1­year 
survival rate (81.2% vs 73.4%; p = 0.01); however, the me-
dian overall survival (OS) rate (26.7 vs 25.2 months, HR 0.88; 
p = 0.16) was similar between the 2 groups. These results 
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Grade 3­4 hypertension was more common in patients re-
ceiving bevacizumab (14.8% vs 0%; p<0.001). Proteinuria 
was also more common in the experimental arm, but was 
rarely clinically significant (grade 3 proteinuria 2.7% vs 0%, 
respectively; p<0.001). No differences in quality of life were 
observed between the 2 groups. Interestingly, an exploratory 
analysis of the ECOG 2100 data showed that patients who 
had received prior taxane­based adjuvant therapy also ben-
efitted from the addition of bevacizumab (18).
AVADO
The AVADO (Avastin and docetaxel) trial, a randomized, 
double­blind, placebo­controlled trial, investigated the ef-
ficacy of docetaxel alone or with bevacizumab at a dose of 
7.5 or 15 mg/kg as first­line therapy in patients with HER2­
negative MBC (22). The primary endpoint was PFS. This study, 
however, was not designed to detect a statistically significant 
difference between bevacizumab doses. Patients (n = 736) 
were randomized to either docetaxel (100 mg/m2) every 21 
days with bevacizumab at a dose of 7.5 mg/kg or 15 mg/
kg or docetaxel with placebo, for a maximum of 9 cycles of 
docetaxel. Earlier discontinuation was allowed for drug intol-
erability. Two dose reductions, to 75 mg/m2 and/or 60 mg/
m2, were also allowed. Continuation on bevacizumab or pla-
cebo as maintenance therapy until disease progression was 
permitted following discontinuation of docetaxel. The major-
ity of patients (75%) had received prior anthracycline­ and/
or taxane­based adjuvant chemotherapy. After progression, 
all patients were given the option to receive bevacizumab 
in combination with second­line regimens. The association 
of bevacizumab with docetaxel showed superior PFS com-
pared to placebo plus docetaxel, at both 7.5 mg/kg (9.0 vs 
8.1 months, stratified HR 0.8; p = 0.045) and 15 mg/kg (10.0 
vs 8.1 months, stratified HR 0.67; p<0.001). Both doses of 
bevacizumab were also associated with significantly higher 
ORRs (7.5 mg/kg: 55.2% vs 46.4%; p = 0.07; 15 mg/kg: 64.1% 
vs 46.4%; p<0.001). However, as in the ECOG 2100 study, the 
rate of OS was similar across all 3 arms, with median values of 
31 months (HR 1.05; p = 0.72 for bevacizumab at 7.5 mg/kg; 
HR 1.03; p = 0.85 for bevacizumab at 15 mg/kg). The addi-
tion of bevacizumab to docetaxel had limited impact on the 
known toxicity profile of docetaxel.
RIBBON-1
The Regimens in Bevacizumab for Breast Oncology (RIB-
BON)­1 trial was an international, multicenter, phase III, 
placebo­controlled trial. Patients (n = 1,237) were randomly 
assigned 2:1 to receive either chemotherapy (capecitabine, 
taxane­based, or anthracycline­based chemotherapy) plus 
bevacizumab or chemotherapy plus placebo, as first­line 
treatment for HER2­negative MBC (23). The primary end-
point was PFS. Secondary endpoints included ORR, OS, and 
1­year survival rate. The combination of bevacizumab and 
chemotherapy as first­line therapy resulted in a statistically 
significant improvement in PFS. In the taxane or anthracycline 
 cohort, median PFS resulted in 9.2 versus 8.0 months (HR 
0.64; 95% confidence interval [CI] 0.52­0.80; p<0.001). Simi-
larly, capecitabine plus bevacizumab significantly improved 
PFS compared with capecitabine alone (8.6 vs 5.7 months; HR 
0.69; CI 0.56­0.84; p<0.001). However, there was no statisti-
cally significant improvement in OS or the 1­year survival rate 
between treatment arms for either cohort. For the cohort of 
patients who received capecitabine, the estimated HR for OS 
was 0.85 (95% CI 0.63­1.14; p = 0.27), and there was a trend 
for improved 1­year survival in the bevacizumab­containing 
arm (81.0% vs 74.4%; p = 0.076). For patients who received 
anthracyclines or taxanes (with or without bevacizumab), 
the stratified HR for OS was 1.03 (95% CI 0.77­1.38; log­rank 
p = 0.83), and the 1­year survival rate was 83.2% versus 80.7% 
(p = 0.44). 
Meta-analyses show improved PFS but not OS
A meta­analysis performed by Miles et al (24) (n = 2,447) 
determined that bevacizumab increased PFS compared with 
non­bevacizumab therapy (HR 0.64, 95% CI 0.57­0.71; medi-
an PFS 9.2 months vs 6.7 months) and also improved the ORR 
(49% vs 32%). However, there was no significant difference in 
OS between the bevacizumab and non­bevacizumab cohorts 
(HR 0.97, 95% CI 0.86-1.08; median OS 26.7 vs 26.4 months). 
One­year survival rate was significantly increased in the beva-
cizumab arms (77% vs 82%; p = 0.003). Furthermore, bevaci-
zumab in poor­prognosis patients with triple­negative MBC 
prolonged PFS (HR 0.63; 95% CI 0.52­0.76) without statistical-
ly significant improvement in OS (HR 0.96; 95% CI 0.79­1.16). 
The median PFS was 8.1 months with bevacizumab versus 
5.4 months with chemotherapy alone, while the median OS 
was 18.9 versus 17.5 months, and the 1­year OS rates were 
71% versus 65%.
These results were similar to those of previously published 
meta­analyses that evaluated the efficacy of bevacizumab in 
combination with chemotherapy for the first­line treatment 
of MBC. A meta­analysis by Valachis et al (25) pooled data 
from the 3 randomized studies E2100, AVADO, and RIBBON­1, 
a phase II study, and a trial with bevacizumab after first­line 
chemotherapy for MBC, and found that the addition of bev-
acizumab first­line MBC significantly improved PFS, with a 
global HR of 0.70 (95% CI 0.60­0.82; p<0.001). This benefit in 
PFS was seen across different subgroups and independently 
from sites of metastases, hormone receptor status, or prior 
adjuvant taxane treatment. The addition of bevacizumab to 
chemotherapy was also related to a significant improvement 
in ORR (p<0.001). However, no significant increases in OS 
were observed in the bevacizumab­containing arms, with a 
global HR of 0.90 (95% CI 0.80­1.03; p = 0.119).
Lee et al (26) evaluated 4 studies involving a total of 2,860 
patients and reported improvement in PFS for patients treat-
ed in bevacizumab­containing arms (pooled HR 0.69, 95% CI 
0.58­0.81), but not OS (HR 0.92, 95% CI 0.82­1.03) or ORR (HR 
1.53, 95% CI 1.37-1.71).
Rossari et al (27) performed a meta­analysis on the E2100, 
AVADO, and RIBBON­1 studies. They found that adding beva-
cizumab to chemotherapy in the first­line treatment of MBC 
significantly improved PFS, with an overall HR of 0.70 (95% 
CI 0.57­0.86; p = 0.0006). The PFS was assessed according to 
hormone receptor status (positive or negative), prior adju-
vant chemotherapy (yes or no), age (<65 years vs ≥65 years), 
prior use of taxanes (yes or no), and disease-free interval 
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(DFI) (short vs long). It was noted that the analysis by DFI was 
different among the trials, with the AVADO and E2100 trials 
stratifying DFI by ≤24 months versus >24 months, whereas 
RIBBON­1 stratified by ≤12 months versus >12 months. How-
ever, adding bevacizumab to chemotherapy provided a con-
sistent benefit in PFS in all the patient subgroups analyzed. 
Nevertheless, none of the individual studies showed a signifi-
cant OS benefit of combining bevacizumab with chemother-
apy and, globally, no statistically significant OS benefit (HR 
0.95, 95% CI 0.85 to 1.06; p = 0.65) was reported.
ATHENA real-world study
ATHENA was an open­label, single­arm, international 
study conducted in a real­world oncology practice setting and 
included a total of 2,251 patients with MBC who received first­
line therapy with bevacizumab plus taxane monotherapy or 
combination chemotherapy. ATHENA was the largest study of 
patients with MBC treated with bevacizumab­containing che-
motherapy regimens to be carried out in a broad community­
based population (28) more closely representative of routine 
clinical oncology practice. The primary objective was safety. 
Secondary endpoints were time to progression (TTP) and OS. 
Patients in this study received, at the discretion of treating 
oncologists, bevacizumab 10 mg/kg every 2 weeks or 15 mg/kg 
every 3 weeks plus taxane­based chemotherapy or other non­
anthracycline regimen until disease progression, unacceptable 
toxicity, or patient withdrawal (28). The majority of patients 
had primarily estrogen receptor­positive BC (66.1%) and more 
than 3 metastatic sites (64%). Chemotherapeutic agents more 
frequently combined with bevacizumab were single­agent pa-
clitaxel (35%) or docetaxel (33%). The paclitaxel administration 
was weekly in 17% of cases, versus 13% every 3 weeks or other 
schedule in 6%. A further 10% of patients received taxane­
based combination regimens, commonly with carboplatin and 
gemcitabine. The non­taxane chemotherapies most frequently 
utilized were capecitabine (5%) and vinorelbine (3%). The me-
dian treatment duration of treatment was 6.2 months for bev-
acizumab (range 0.0­29.7) and 4.2 months for chemotherapy 
(range 0.0-29.5).
Safety and efficacy data were consistent with the findings 
of the previous reported randomized clinical trials of chemo-
therapy evaluating bevacizumab in combination with first­
line taxane­based regimens for locally recurrent BC or MBC. 
 First­line bevacizumab in combination with taxane­based che-
motherapy was well­tolerated, with a low incidence of severe 
adverse events (SAEs) or specific adverse events (AEs) in a 
broad population of BC patients (28). The most frequent SAEs 
were febrile neutropenia (5.1%), neutropenia (3.6%), and py-
rexia (1.5%). The incidence of grade 3­4 hypertension was 4.4%, 
lower than that reported in E2100 (16%), but similar to AVADO 
(4.5%). Furthermore, other bevacizumab­ related SAEs of grade 
3 or higher were uncommon and consisted of arterial/venous 
thromboembolism (3.3%), proteinuria (1.7%), gastrointestinal 
perforation (0.26%), and congestive heart failure (0.44%). The 
overall median TTP was 9.5 months (95% CI 9.1­9.9). The ORR in 
the intent­to­treat (ITT) population was 52% and a further 33% 
of patients achieved disease stabilization as their best response.
Final survival data from the ATHENA study after a medi-
an follow­up duration of 20.1 months showed that OS was 
25.2 months in patients receiving bevacizumab in combina-
tion with standard first­line chemotherapy (29). Furthermore, 
for patients who continued bevacizumab monotherapy after 
stopping chemotherapy, median TTP was 11.6 months and 
median OS 30.0 months (29).
Interestingly, a subanalysis in the elderly subpopulation 
of the ATHENA study was published, comprising 175 patients 
aged ≥70 years (30). Approximately half of these patients 
(46%) received a paclitaxel regimen in combination with bev-
acizumab. The combination was well­tolerated by elderly pa-
tients. The median TTP in this subpopulation was 10.4 months 
(95% CI 8.8­11.8 months), compared with 9.5 months (95% 
CI 9.1­9.9) in the overall ITT population. The ORR was 42% 
for the elderly patients, compared with 52% in the overall ITT 
population. Final survival data in this patient group showed a 
median OS of 20.4 months. Moreover, the overall incidence 
of bevacizumab­related SAEs was similar to that reported in 
younger patients (<70 years). The only grade ≥3 SAEs more 
commonly reported in older versus younger patients were 
hypertension (6.9% vs 4.2%) and proteinuria (4.0% vs 1.5%). 
The incidences of grade 3 or higher arterial/venous thrombo-
embolic events (2.9%vs 3.3%), CNS hemorrhage (<0.1%), and 
cardiac events (0.6 vs 0.4%) were similar to younger patients. 
Efficacy of bevacizumab plus paclitaxel
A recent study confirmed that the addition of bevacizum-
ab to a paclitaxel­based regimen was an active and well­tol-
erated first­line treatment for MBC (31). In 220 patients with 
previously untreated MBC, the combination of bevacizumab 
plus paclitaxel resulted in a median PFS of 9.3 months (95% CI 
7.8-10.8) and a 1-year survival rate of 68%. This regimen also 
presented notable activity in patients with triple­negative 
BC (TNBC; n = 106) with a median PFS of 8.3 months (95% 
CI 7.8­8.8). Severe AEs were consistent with the established 
safety profile of bevacizumab plus paclitaxel.
Discussion
The combination of bevacizumab with taxane­based regi-
mens has been associated with benefits in ORR and PFS in the 
first­line treatment of patients with locally recurrent BC or 
MBC (32). However, to date, no significant OS advantage has 
been observed in randomized clinical trials. The RIBBON­2 
study showed a trend towards a benefit in OS with bevaci-
zumab, even though the benefit in OS was not statistically 
significant (33). The open­label, single­arm, international, re-
al­world ATHENA trial also reported a notable OS in patients 
receiving bevacizumab in combination with standard first­line 
chemotherapy, also including elderly population, and, above 
all, for patients who received maintenance with bevacizumab 
monotherapy after stopping chemotherapy (29). The RIB-
BON­2 trial only included pretreated patients, and ATHENA 
was in patients not previously treated for metastatic dis-
ease. Although the benefit was persistent in the TNBC and 
elderly subgroups, no clear benefit on OS was demonstrated 
(30, 34). Furthermore, the single­arm ATHENA trial does not 
allow us to define the impact of the addition of bevacizum-
ab to chemotherapy. Nevertheless, its large sample size (n = 
2,251) could provide valuable information on outcomes in 
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clinically important subgroups, including patients with TNBC 
and the elderly. The results of a multicenter national French 
observational study, based on a large­scale real­life setting da-
tabase, the Epidemiological Strategy and Medical Economics 
program, were presented at the recent American Society of 
Clinical Oncology annual meeting (35). Significantly better OS 
was reported in the 2,127 patients with HER2­negative MBC 
who received paclitaxel plus bevacizumab, compared with 
the 1,299 patients receiving paclitaxel alone (HR 0.672 [95% 
CI 0.601, 0.752]; median survival time, 27.7 vs 19.8 months). 
Also, PFS was better for patients receiving paclitaxel plus 
bevacizumab versus paclitaxel (HR 0.739 [0.672, 0.813]; 8.1 
vs 6.4 months). All data were consistent across all support-
ive and sensitivity analyses, as well as in triple­negative and 
estrogen receptor­positive subgroups. Concerning this, it is 
worth noting that a robust methodology was applied. Howev-
er, as the same authors concluded, despite the robust meth-
odology, real­world data should be interpreted with caution.
To be thorough, no benefits were reported in patients 
with earlier stage BC with the addition of bevacizumab in the 
adjuvant setting (36, 37). However, this is not a subject of this 
review.
In MBC, due to the lack of a clear survival benefit associ-
ated with bevacizumab, the FDA recommended against beva-
cizumab in 2010 (19, 20). The FDA revocation resulted from 
concerns about safety, considering that bevacizumab did not 
improve OS in different randomized studies.
One of the major problems has been its lack of an OS ben-
efit. However, there is no unanimous opinion on the appro-
priateness of OS as a sole primary endpoint in first­line MBC 
clinical trials, which has been the subject of lively debate. 
Interestingly, Cortés et al (38) reported that, even though 
from a regulatory standpoint gain in OS is the gold standard 
for drug approval, PFS could be a valid surrogate endpoint in 
some diseases and in specific treatment settings. 
The value of PFS in the context of MBC remains contro-
versial. However, PFS has several important advantages in 
MBC trials. To date, patients with MBC usually receive mul-
tiple lines of subsequent therapy (Tab. II), and PFS/TTP should 
be considered true endpoints since they are not affected by 
subsequent lines of chemotherapy. In MBC, a strikingly small 
proportion of all trials (12%), and even fewer first­line trials 
(4.8%), demonstrated OS gain. According to the model pro-
posed by Broglio and Berry (39) on post­progression survival 
(PPS), OS would be an appropriate primary endpoint when 
there is a short median PPS interval. On the other hand, when 
the PPS is >12 months, subsequent lines of chemotherapy 
would dilute the effect of the study medication on OS. In 
MBC, the ability of first­line phase III trials to demonstrate 
a treatment effect upon OS depends on the duration of PPS 
(40, 41). Indeed, OS may be a more appropriate endpoint 
for second­ or third­line trials, when PPS is shorter. This is il-
lustrated by the recent EMBRACE trial in heavily pretreated 
patients with anthracycline­ and taxane­refractory MBC who 
were randomized to monotherapy with the microtubule in-
hibitor eribulin or treatment of physician’s choice. Eribulin 
significantly improved OS (median 13.1 months, 95% CI 11.8­
14.3) compared with the real­life standard treatment choices 
(10.6 months, 95% CI 9.3-12.5; HR 0.81, 95% CI 0.66-0.99; 
p = 0.041) (42).
Moreover, these clinical trials did not collect data on post­
progression therapies. Without details on subsequent treat-
ments, it would be impossible to determine the impact of 
different post­trial therapies patients received in the bevaci-
zumab and non­bevacizumab arms. Furthermore, the lack of 
statistically significant OS benefit could be due to the cross­
over to bevacizumab allowed to patients in non­bevacizumab 
arms at the time of progression (22, 23).
Several issues arise over the FDA’s removal of the BC indi-
cation for bevacizumab. If this decision was based on a lack of 
OS benefit, it is unclear why the indications for bevacizumab 
in other cancers remain, particularly as a clear OS survival 
benefit has not been established for the majority of cytotoxic 
chemotherapy combinations in current use in MBC. Even the 
most well­established cytotoxic regimens show at best only 
marginally significant OS benefits (43, 44), which makes the 
FDA’s decision appear at least controversial, if not arbitrary.
The FDA cited primarily safety-related concerns for its 
reasons to remove the MBC indication for bevacizumab (45). 
These toxicities include hypertension, proteinuria, thrombo-
sis, and hemorrhage (46). However, as previously reported 
in available MBC phase III safety data (AVF2119g, E2100, 
AVADO, RIBBON­1, and RIBBON­2), bevacizumab generally 
appeared to be well­tolerated (18, 22, 23, 33, 47). Typically, 
SAEs occurring during treatment with bevacizumab are pre-
dictable, mild to moderate in severity, and/or manageable 
with standard medication, and usually do not necessitate 
discontinuation of therapy. In general, bevacizumab has been 
shown to have a favorable tolerability profile when used in 
various combination therapy approaches, including in special 
populations such as the elderly and patients with poor perfor-
mance status (48). However, AEs such as arterial thrombosis 
and cardiac toxicity, although uncommon with bevacizumab, 
are more serious and require appropriate clinical awareness 
and prudent monitoring.
Regarding cost, bevacizumab seems expensive and 
not  cost­effective as a first­line treatment for MBC. The 
 cost­effectiveness of bevacizumab in combination with 
paclitaxel­based chemotherapy has been assessed using a 
tABLE II -  Use of subsequent systemic therapies in the AVADO (22) 
and RIBBON-1 (23) studiesa
Non-bevacizumab 
(n = 654)
Bevacizumab 
(n = 1,071)
Systemic therapies,  
% patients
 Any chemotherapy 71 65
 Bevacizumab 51 40
 Any hormonal therapy 25 23
No. of lines of subsequent 
anticancer therapies
 ≥4 27 23
 3 15 12
 2 27 26
 1 10 15
a Data were not available from the E2100 study.
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decision­ analytical model incorporating efficacy and ad-
verse events data from the ECOG 2100 trial (49­51). This is 
not only related to bevacizumab of course, but it is common 
for almost all new drugs now employed in the treatment of 
cancer (breast or other). Most of the combinations with new 
agents recently approved for the treatment of cancer did 
not demonstrate a clear advantage in OS, including expen-
sive combinations of anti­HER2 agents with endocrine ther-
apy for MBC (52, 53) or the most expensive drugs employed 
in other cancer types, for example trabectedin in ovarian 
cancer (54, 55). Nevertheless, physicians who have access 
to expensive interventions have a responsibility to consider 
the cost­effectiveness of cancer drugs as part of their role 
as overseers of finite health care resources (56, 57). Tak-
ing into consideration very limited healthcare budgets, al-
ternative solutions such as risk­sharing schemes should be 
considered. To this end, risk­sharing schemes for pharma-
ceuticals can be regarded as agreements between payers 
and pharmaceutical companies with the aim of reducing the 
impact of new and existing medicines on the payer’s budget 
where there is uncertainty regarding the value of the medi-
cine and/or the need to work within finite budgets.
Strategies to accelerate reimbursement and improve ac-
cess for newer and potentially innovative medicines, particu-
larly where limited data are available at the time of marketing 
approval, have recently been initiated by the Italian Medi-
cines Agency (AIFA), using 2 different approaches: variations 
on patient access schemes and performance­based/outcome 
contracts (where the pharmaceutical company reimburses 
the cost if the medicine is shown to be ineffective and the 
National Health Service pays for effective medicines) (58­60). 
The AIFA Oncologic Working Group proposed 2 risk­sharing 
arrangements for new anticancer drugs to enhance their re-
imbursement potential according to the following criteria: 
“epidemiological data for the disease; the possibility of clearly 
defining a subset of the population responsive to the treat-
ment; and results from clinical trials” (60). Bevacizumab—for 
metastatic carcinoma of the colon or rectum, BC, non­small­
cell lung cancer, and advanced and/or metastatic renal cell 
cancer—was included in this scheme.
Conclusion
The addition of bevacizumab to chemotherapy has pro-
duced substantial improvements in ORR and PFS, compared 
with chemotherapy alone, in advanced HER2­negative BC. 
However, no significant OS improvement has been observed 
so far, and further follow­up is needed. Still to be answered 
from currently available and emerging data is whether pro-
longation of PFS is in itself enough to consider bevacizumab 
efficacious in MBC. Moreover, it should be noted that beva-
cizumab was well­tolerated in studies in patients with MBC, 
and AEs were fairly manageable, with remarkably similar fre-
quencies of bevacizumab­related AEs when combined with 
a number of different anticancer drugs. Patients with TNBC 
seem particularly well­suited to bevacizumab treatment. 
 Finally, the cost of treatment with bevacizumab is consistent 
with the costs of other generally accepted new anticancer 
treatments, and should therefore not be considered a deter-
rent to its use in MBC.
To date, there is no role for bevacizumab for the treat-
ment of early­stage BC. On the other hand, bevacizumab, 
based on the available clinical trials results, is a part of the 
complex therapeutic context of MBC. The identification of 
biomarkers would be useful to optimize its use in MBC.
Acknowledgment
The authors thank Health Publishing & Services, Milan, Italy, for edit-
ing assistance.
Disclosures
Financial support: No financial support was received for this submis-
sion.
Conflict of interest: P. Marchetti has received grants from Astra-
Zeneca, Novartis, Roche, Bristol Myers Squibb, and GlaxoSmith-
Kline. None of the other authors has conflict of interest with this 
submission.
References
1. Lohmann AE, Chia S. Patients with metastatic breast cancer us-
ing bevacizumab as a treatment: is there still a role for it? Curr 
Treat Options Oncol. 2012;13(2):249­262.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 
2005;438(7070):932-936.
3. Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of 
disease: angiogenesis and the management of breast cancer. 
Nat Clin Pract Oncol. 2007;4(9):536-550.
4. Ferrara N, Davis­Smyth T. The biology of vascular endothelial 
growth factor. Endocr Rev. 1997;18(1):4­25.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its 
receptors. Nat Med. 2003;9(6):669­676.
6. Folkman J. Tumor angiogenesis: therapeutic implications. N 
Engl J Med. 1971;285(21):1182­1186.
7. Jain RK. Normalizing tumor vasculature with anti­angiogenic 
therapy: a new paradigm for combination therapy. Nat Med. 
2001;7(9):987-989.
8. Korpanty G, Sullivan LA, Smyth E, Carney DN, Brekken RA. Mo-
lecular and clinical aspects of targeting the VEGF pathway in 
tumors. J Oncol. 2010;2010:652320.
9. Jain RK. Normalization of tumor vasculature: an emerging 
concept in antiangiogenic therapy. Science. 2005;307(5706): 
58-62.
10. Manders P, Beex LV, Tjan­Heijnen VC, Span PN, Sweep CG. Vas-
cular endothelial growth factor is associated with the efficacy 
of endocrine therapy in patients with advanced breast carci-
noma. Cancer. 2003;98(10):2125-2132.
11. Foekens JA, Peters HA, Grebenchtchikov N, et al. High tumor 
levels of vascular endothelial growth factor predict poor re-
sponse to systemic therapy in advanced breast cancer. Cancer 
Res. 2001;61(14):5407-5414.
12. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, 
double­blind, placebo­controlled phase III trial of chemother-
apy with or without bevacizumab in patients with platinum­
sensitive recurrent epithelial ovarian, primary peritoneal, or 
fallopian tube cancer. J Clin Oncol. 2012;30(17):2039­2045.
13. Sandler A, Gray R, Perry MC, et al. Paclitaxel­carboplatin alone 
or with bevacizumab for non­small­cell lung cancer. N Engl J 
Med. 2006;355(24):2542­2550.
14. Escudier B, Pluzanska A, Koralewski P, et al; AVOREN Trial in-
vestigators. Bevacizumab plus interferon alfa­2a for treatment 
of metastatic renal cell carcinoma: a randomised, double­blind 
phase III trial. Lancet. 2007;370(9605):2103-2111.
Sini et al  479
© 2016 The Authors. Published by Wichtig Publishing
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab 
plus irinotecan, fluorouracil, and leucovorin for metastatic 
colorectal cancer. N Engl J Med. 2004;350(23):2335­2342.
16. Stark D, Nankivell M, Pujade­Lauraine E, et al. Standard che-
motherapy with or without bevacizumab in advanced ovarian 
cancer: quality­of­life outcomes from the International Col-
laboration on Ovarian Neoplasms (ICON7) phase 3 randomised 
trial. Lancet Oncol. 2013;14(3):236-243.
17. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single­agent 
bevacizumab followed by bevacizumab plus irinotecan at tu-
mor progression in recurrent glioblastoma. J Clin Oncol. 2009; 
27(5):740-745.
18. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab 
versus paclitaxel alone for metastatic breast cancer. N Engl J 
Med. 2007;357(26):2666­2676.
19. Allison M. Avastin’s commercial march suffers setback. Nat Bio-
technol. 2010;28(9):879-880.
20. Montero AJ, Vogel C. Fighting fire with fire: rekindling the bev-
acizumab debate. N Engl J Med. 2012;366(4):374­375.
21. Gray R, Bhattacharya S, Bowden C, Miller K, Comis RL. Inde-
pendent review of E2100: a phase III trial of bevacizumab plus 
paclitaxel versus paclitaxel in women with metastatic breast 
cancer. J Clin Oncol. 2009;27(30):4966­4972.
22. Miles DW, Chan A, Dirix LY, et al. Phase III study of bevaci-
zumab plus docetaxel compared with placebo plus docetaxel 
for the first­line treatment of human epidermal growth fac-
tor receptor 2­negative metastatic breast cancer. J Clin Oncol. 
2010;28(20):3239-3247.
23. Robert NJ, Diéras V, Glaspy J, et al. RIBBON­1: randomized, dou-
ble­blind, placebo­controlled, phase III trial of chemotherapy 
with or without bevacizumab for first­line treatment of human 
epidermal growth factor receptor 2­negative, locally recurrent or 
metastatic breast cancer. J Clin Oncol. 2011;29(10):1252­1260.
24. Miles DW, Diéras V, Cortés J, Duenne AA, Yi J, O’Shaughnessy J.  
First­line bevacizumab in combination with chemotherapy 
for HER2­negative metastatic breast cancer: pooled and sub-
group analyses of data from 2447 patients. Ann Oncol. 2013;24 
(11):2773-2780.
25. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V,  
Mavroudis D, Mauri D. Bevacizumab in metastatic breast can-
cer: a meta-analysis of randomized controlled trials. Breast 
Cancer Res Treat. 2010;122(1):1-7.
26. Lee JB, Woo OH, Park KH, et al. Bevacizumab for salvage treat-
ment of metastatic breast cancer: a systemic review and me-
ta­analysis of randomized controlled trials. Invest New Drugs. 
2011;29(1):182-188.
27. Rossari JR, Metzger­Filho O, Paesmans M, Saini KS, Gennari A, 
de Azambuja E et al. Bevacizumab and Breast Cancer: A Meta­
Analysis of First­Line Phase III Studies and a Critical Reappraisal 
of Available Evidence. J Oncol. 2012;2012:417673.
28. Smith IE, Pierga JY, Biganzoli L, et al; ATHENA Study Group. First­
line bevacizumab plus taxane­based chemotherapy for locally 
recurrent or metastatic breast cancer: safety and efficacy in 
an open­label study in 2,251 patients. Ann Oncol. 2011;22(3): 
595-602.
29. Smith I, Pierga JY, Biganzoli L, et al. Final overall survival re-
sults and effect of prolonged (≥1 year) first­line bevacizumab­
containing therapy for metastatic breast cancer in the ATHENA 
trial. Breast Cancer Res Treat. 2011;130(1):133-143.
30. Biganzoli L, Di Vincenzo E, Jiang Z, et al. First­line bevacizum-
ab­containing therapy for breast cancer: results in patients 
aged≥70 years treated in the ATHENA study. Ann Oncol. 2012; 
23(1):111-118.
31. Dank M, Budi L, Piko B, et al. First­line bevacizumab­paclitaxel 
in 220 patients with metastatic breast cancer: results from the 
AVAREG study. Anticancer Res. 2014;34(3):1275­1280.
32. Wagner AD, Thomssen C, Haerting J, Unverzagt S. Vascular­
endothelial­growth­factor (VEGF) targeting therapies for endo-
crine refractory or resistant metastatic breast cancer. Cochrane 
Database Syst Rev. 2012;7(7):CD008941.
33. Brufsky AM, Hurvitz S, Perez E, et al. RIBBON­2: a randomized, 
double­blind, placebo­controlled, phase III trial evaluating the 
efficacy and safety of bevacizumab in combination with che-
motherapy for second-line treatment of human epidermal 
growth factor receptor 2­negative metastatic breast cancer.  
J Clin Oncol. 2011;29(32):4286­4293.
34. Thomssen C, Pierga JY, Pritchard KI, et al. First­line bevacizum-
ab­containing therapy for triple­negative breast cancer: analy-
sis of 585 patients treated in the ATHENA study. Oncology. 
2012;82(4):218-227.
35. Delaloge S, Perol D, Brain E et al. Overall survival of patients 
with HER2­negative metastatic breast cancer treated with a 
first­line paclitaxel with or without bevacizumab in real­life 
setting: Results of a multicenter national observational study 
[Abstract]. J Clin Oncol. 2016;34(15_suppl):1013.
36. Slamon D, Swain S, Buyse M, Martin M, Geyer C, Im Y­H  
et al. Primary results from BETH, a phase 3 controlled study 
of adjuvant chemotherapy and trastuzumab ± bevacizumab in 
patients with HER2­positive, node­positive or high risk node­
negative breast cancer [Abstract]. Cancer Res. 2014;73(24 
Suppl):Abst S1­03.
37. Cameron D, Brown J, Dent R, et al. Adjuvant bevacizumab­
containing therapy in triple­negative breast cancer (BEATRICE): 
primary results of a randomised, phase 3 trial. Lancet Oncol. 
2013;14(10):933-942.
38. Cortés J, Calvo E, González­Martín A, et al. Progress against 
solid tumors in danger: the metastatic breast cancer example. 
J Clin Oncol. 2012;30(28):3444­3447.
39. Broglio KR, Berry DA. Detecting an overall survival benefit that 
is derived from progression­free survival. J Natl Cancer Inst. 
2009;101(23):1642-1649.
40. Saad ED, Katz A, Hoff PM, Buyse M. Progression­free survival as 
surrogate and as true end point: insights from the breast and 
colorectal cancer literature. Ann Oncol. 2010;21(1):7-12.
41. Burzykowski T, Buyse M, Piccart­Gebhart MJ, et al. Evalua-
tion of tumor response, disease control, progression­free 
survival, and time to progression as potential surrogate end 
points in metastatic breast cancer. J Clin Oncol. 2008;26(12): 
1987-1992.
42. Cortés J, O’Shaughnessy J, Loesch D, et al; EMBRACE (Eisai Met-
astatic Breast Cancer Study Assessing Physician’s Choice Versus 
E7389) investigators. Eribulin monotherapy versus treatment 
of physician’s choice in patients with metastatic breast cancer 
(EMBRACE): a phase 3 open­label randomised study. Lancet. 
2011;377(9769):914-923.
43. Piccart­Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes 
alone or in combination with anthracyclines as first­line ther-
apy of patients with metastatic breast cancer. J Clin Oncol. 
2008;26(12):1980-1986.
44. Albain KS, Nag SM, Calderillo­Ruiz G, et al. Gemcitabine plus 
Paclitaxel versus Paclitaxel monotherapy in patients with meta-
static breast cancer and prior anthracycline treatment. J Clin 
Oncol. 2008;26(24):3950-3957.
45. US Food and Drug Administration. FDA begins process to remove 
breast cancer indication from Avastin label 2010. Available from: 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnounce-
ments/ucm237172.htm. Accessed May 30, 2016.
46. Eskens FA, Verweij J. The clinical toxicity profile of vascular 
endothelial growth factor (VEGF) and vascular endothelial 
growth factor receptor (VEGFR) targeting angiogenesis inhibi-
tors; a review. Eur J Cancer. 2006;42(18):3127­3139.
Bevacizumab in HER2-negative advanced breast cancer480 
© 2016 The Authors. Published by Wichtig Publishing
47. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial 
of capecitabine compared with bevacizumab plus capecitabine 
in patients with previously treated metastatic breast cancer. J 
Clin Oncol. 2005;23(4):792-799.
48. Cortés J, Calvo V, Ramírez­Merino N, et al. Adverse events 
risk associated with bevacizumab addition to breast can-
cer chemotherapy: a meta-analysis. Ann Oncol. 2012;23(5): 
1130-1137.
49. Montero AJ, Avancha K, Glück S, Lopes G. A cost­benefit analy-
sis of bevacizumab in combination with paclitaxel in the first­
line treatment of patients with metastatic breast cancer. Breast 
Cancer Res Treat. 2012;132(2):747-751.
50. Dedes KJ, Matter­Walstra K, Schwenkglenks M, et al. Bevaci-
zumab in combination with paclitaxel for HER­2 negative meta-
static breast cancer: an economic evaluation. Eur J Cancer. 
2009;45(8):1397-1406.
51. Lopes G, Glück S, Avancha K, Montero AJ. A cost effective-
ness study of eribulin versus standard single­agent cytotoxic 
chemotherapy for women with previously treated meta-
static breast cancer. Breast Cancer Res Treat. 2013;137(1): 
187-193.
52. Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus 
anastrozole versus anastrozole alone for the treatment of 
postmenopausal women with human epidermal growth fac-
tor receptor 2­positive, hormone receptor­positive metastatic 
breast cancer: results from the randomized phase III TAnDEM 
study. J Clin Oncol. 2009;27(33):5529­5537.
53. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with 
letrozole versus letrozole and placebo as first­line therapy for 
postmenopausal hormone receptor­positive metastatic breast 
cancer. J Clin Oncol. 2009;27(33):5538­5546.
54. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated 
liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 
2010;28(19):3107-3114.
55. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pe-
gylated liposomal doxorubicin (PLD) versus PLD in recurrent 
ovarian cancer: overall survival analysis. Eur J Cancer. 2012; 
48(15):2361-2368.
56. Caplan AL. Will evidence ever be sufficient to resolve the 
challenge of cost containment? J Clin Oncol. 2011;29(15): 
1946-1948.
57. Uyl­de Groot C, de Vries EGE, Verweij J, Sullivan R. A., de 
Vries EGE, Verweij J, Sullivan R. Dispelling the myths around 
cancer care delivery: It’s not all about costs. J Cancer Policy. 
2014;2(1):22-29.
58. McCabe C, Bergmann L, Bosanquet N, et al; Biotherapy Devel-
opment Association. Market and patient access to new oncol-
ogy products in Europe: a current, multidisciplinary perspec-
tive. Ann Oncol. 2009;20(3):403­412.
59. Stafinski T, McCabe CJ, Menon D. Funding the unfundable: 
mechanisms for managing uncertainty in decisions on the in-
troduction of new and innovative technologies into healthcare 
systems. Pharmacoeconomics. 2010;28(2):113-142.
60. Folino Gallo P, Deambrosis P. Pharmaceutical risk­sharing and 
conditional reimbursement in Italy. Central and Eastern Euro-
pean Society of Technology Assessment in Health Care (CEES-
TAHC) 2008. Available from: http://www.ceestahc.org/pliki/
symp2008/gallo.pdf.
